These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 28429216

  • 1. Effect of N- and C-Terminal Modifications on Cytotoxic Properties of Antimicrobial Peptide Tachyplesin I.
    Kuzmin DV, Emelianova AA, Kalashnikova MB, Panteleev PV, Ovchinnikova TV.
    Bull Exp Biol Med; 2017 Apr; 162(6):754-757. PubMed ID: 28429216
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Comparative in vitro study on cytotoxicity of recombinant β-hairpin peptides.
    Kuzmin DV, Emelianova AA, Kalashnikova MB, Panteleev PV, Balandin SV, Serebrovskaya EO, Belogurova-Ovchinnikova OY, Ovchinnikova TV.
    Chem Biol Drug Des; 2018 Jan; 91(1):294-303. PubMed ID: 28815904
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Hairpin structure stability plays a role in the activity of two antimicrobial peptides.
    Sivanesam K, Kier BL, Whedon SD, Chatterjee C, Andersen NH.
    FEBS Lett; 2016 Dec; 590(24):4480-4488. PubMed ID: 27859052
    [Abstract] [Full Text] [Related]

  • 6. Improved strategy for recombinant production and purification of antimicrobial peptide tachyplesin I and its analogs with high cell selectivity.
    Panteleev PV, Ovchinnikova TV.
    Biotechnol Appl Biochem; 2017 Jan; 64(1):35-42. PubMed ID: 26549611
    [Abstract] [Full Text] [Related]

  • 7. Experimental Induction of Bacterial Resistance to the Antimicrobial Peptide Tachyplesin I and Investigation of the Resistance Mechanisms.
    Hong J, Hu J, Ke F.
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6067-75. PubMed ID: 27480861
    [Abstract] [Full Text] [Related]

  • 8. Effects and mechanisms of the secondary structure on the antimicrobial activity and specificity of antimicrobial peptides.
    Mai XT, Huang J, Tan J, Huang Y, Chen Y.
    J Pept Sci; 2015 Jul; 21(7):561-8. PubMed ID: 25826179
    [Abstract] [Full Text] [Related]

  • 9. In Vitro Study of Antitumor Effect of Antimicrobial Peptide Tachyplesin I in Combination with Cisplatin.
    Kuzmin DV, Emel'yanova AA, Kalashnikova MB, Panteleev PV, Ovchinnikova TV.
    Bull Exp Biol Med; 2018 Jun; 165(2):220-224. PubMed ID: 29922995
    [Abstract] [Full Text] [Related]

  • 10. Characterization of Tachyplesin Peptides and Their Cyclized Analogues to Improve Antimicrobial and Anticancer Properties.
    Vernen F, Harvey PJ, Dias SA, Veiga AS, Huang YH, Craik DJ, Lawrence N, Troeira Henriques S.
    Int J Mol Sci; 2019 Aug 26; 20(17):. PubMed ID: 31455019
    [Abstract] [Full Text] [Related]

  • 11. Interactions of an antimicrobial peptide, tachyplesin I, with lipid membranes.
    Matsuzaki K, Fukui M, Fujii N, Miyajima K.
    Biochim Biophys Acta; 1991 Nov 18; 1070(1):259-64. PubMed ID: 1751532
    [Abstract] [Full Text] [Related]

  • 12. Mode of action of an antimicrobial peptide, tachyplesin I, on biomembranes.
    Katsu T, Nakao S, Iwanaga S.
    Biol Pharm Bull; 1993 Feb 18; 16(2):178-81. PubMed ID: 7689887
    [Abstract] [Full Text] [Related]

  • 13. Deletion of all cysteines in tachyplesin I abolishes hemolytic activity and retains antimicrobial activity and lipopolysaccharide selective binding.
    Ramamoorthy A, Thennarasu S, Tan A, Gottipati K, Sreekumar S, Heyl DL, An FY, Shelburne CE.
    Biochemistry; 2006 May 23; 45(20):6529-40. PubMed ID: 16700563
    [Abstract] [Full Text] [Related]

  • 14. In vitro activities of tachyplesin III against Pseudomonas aeruginosa.
    Cirioni O, Giacometti A, Kamysz W, Silvestri C, Riva A, Della Vittoria A, Abbruzzetti A, Lukasiak J, Scalise G.
    Peptides; 2007 Apr 23; 28(4):747-51. PubMed ID: 17331619
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. D-Amino Acid Analogues of the Antimicrobial Peptide CDT Exhibit Anti- Cancer Properties in A549, a Human Lung Adenocarcinoma Cell Line.
    Evans HG, Guthrie JW, Jujjavarapu M, Hendrickson N, Eitel A, Park Y, Garvey J, Newman R, Esckilsen D, Heyl DL.
    Protein Pept Lett; 2017 Apr 23; 24(7):590-598. PubMed ID: 28641565
    [Abstract] [Full Text] [Related]

  • 17. Heterologous expression of a broad-spectrum chimeric antimicrobial peptide in Lactococcus lactis: Its safety and molecular modeling evaluation.
    Tanhaieian A, Sekhavati MH, Ahmadi FS, Mamarabadi M.
    Microb Pathog; 2018 Dec 23; 125():51-59. PubMed ID: 30208331
    [Abstract] [Full Text] [Related]

  • 18. Mechanism of tachyplesin I injury to bacterial membranes and intracellular enzymes, determined by laser confocal scanning microscopy and flow cytometry.
    Hong J, Guan W, Jin G, Zhao H, Jiang X, Dai J.
    Microbiol Res; 2015 Jan 23; 170():69-77. PubMed ID: 25267486
    [Abstract] [Full Text] [Related]

  • 19. Binding of tachyplesin I to DNA revealed by footprinting analysis: significant contribution of secondary structure to DNA binding and implication for biological action.
    Yonezawa A, Kuwahara J, Fujii N, Sugiura Y.
    Biochemistry; 1992 Mar 24; 31(11):2998-3004. PubMed ID: 1372516
    [Abstract] [Full Text] [Related]

  • 20. Conformation and antimicrobial activity of linear derivatives of tachyplesin lacking disulfide bonds.
    Rao AG.
    Arch Biochem Biophys; 1999 Jan 01; 361(1):127-34. PubMed ID: 9882437
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.